ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Bayer AG (PK)

Bayer AG (PK) (BAYZF)

22.2253
-0.3297
(-1.46%)
Closed 20 February 8:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
22.2253
Bid
21.67
Offer
22.63
Volume
310
22.2253 Day's Range 22.2253
19.50 52 Week Range 34.0138
Market Cap
Previous Close
22.555
Open
22.2253
Last Trade
225
@
22.2253
Last Trade Time
Financial Volume
US$ 6,890
VWAP
22.2253
Average Volume (3m)
16,919
Shares Outstanding
982,424,082
Dividend Yield
0.95%
PE Ratio
-7.23
Earnings Per Share (EPS)
-2.99
Revenue
47.64B
Net Profit
-2.94B

About Bayer AG (PK)

Sector
Chems, Allied Pds-whsl, Nec
Industry
Chemicals & Allied Products
Website
Headquarters
Leverkusen, Deu
Founded
1998
Bayer AG (PK) is listed in the Chems, Allied Pds-whsl sector of the OTCMarkets with ticker BAYZF. The last closing price for Bayer (PK) was US$22.56. Over the last year, Bayer (PK) shares have traded in a share price range of US$ 19.50 to US$ 34.0138.

Bayer (PK) currently has 982,424,082 shares in issue. The market capitalisation of Bayer (PK) is US$22.16 billion. Bayer (PK) has a price to earnings ratio (PE ratio) of -7.23.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.77533.6144522144521.4522.7621.45113722.12752419CS
40.40531.8574702108221.8222.7621.4421951222.05514799CS
121.84539.0544651619220.3822.7619.51691920.97431629CS
26-9.9247-30.869984447932.1534.013819.51602822.43093682CS
52-9.0447-28.924528301931.2734.013819.51831126.50455818CS
156-36.1347-61.916895133758.3674.3419.52246745.90048256CS
260-58.7747-72.56135802478184.4919.51670349.08721903CS

BAYZF - Frequently Asked Questions (FAQ)

What is the current Bayer (PK) share price?
The current share price of Bayer (PK) is US$ 22.2253
How many Bayer (PK) shares are in issue?
Bayer (PK) has 982,424,082 shares in issue
What is the market cap of Bayer (PK)?
The market capitalisation of Bayer (PK) is USD 22.16B
What is the 1 year trading range for Bayer (PK) share price?
Bayer (PK) has traded in the range of US$ 19.50 to US$ 34.0138 during the past year
What is the PE ratio of Bayer (PK)?
The price to earnings ratio of Bayer (PK) is -7.23
What is the cash to sales ratio of Bayer (PK)?
The cash to sales ratio of Bayer (PK) is 0.45
What is the reporting currency for Bayer (PK)?
Bayer (PK) reports financial results in EUR
What is the latest annual turnover for Bayer (PK)?
The latest annual turnover of Bayer (PK) is EUR 47.64B
What is the latest annual profit for Bayer (PK)?
The latest annual profit of Bayer (PK) is EUR -2.94B
What is the registered address of Bayer (PK)?
The registered address for Bayer (PK) is KAISER-WILHELM-ALLEE 1, LEVERKUSEN, 51368
What is the Bayer (PK) website address?
The website address for Bayer (PK) is www.bayer.com
Which industry sector does Bayer (PK) operate in?
Bayer (PK) operates in the CHEMICALS & ALLIED PRODUCTS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RGRLFRio Grande Resources Ltd
 0.07
(34,900.00%)
9k
TPIITriad Pro Innovators Inc (CE)
US$ 0.0002
(19,900.00%)
14k
HLLPFHello Pal International Inc (CE)
US$ 0.0002
(19,900.00%)
40.2k
AFIIQArmstrong Flooring Inc (CE)
US$ 0.0001
(9,900.00%)
10.89k
ONCIOn4 Communications Inc (PK)
US$ 0.0001
(9,900.00%)
6.4M
SPIEFSPI Energy Company Ltd (CE)
US$ 0.000001
(-100.00%)
59.69k
SHWZMedicine Man Technologies Inc (CE)
US$ 0.000001
(-100.00%)
2k
RQHTFReliq Health Technologies Inc (CE)
US$ 0.000001
(-99.99%)
350
NLVVFNew Leaf Ventures (PK)
US$ 0.000001
(-99.98%)
400
CDBTChina Dasheng Biotechnology Company (PK)
US$ 0.0003
(-99.63%)
1.17k
BOTYLingerie Fighting Championships Inc (PK)
US$ 0.0001
(0.00%)
443.07M
RONNRonn Motor Group Inc (PK)
US$ 0.0004
(33.33%)
433.99M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.000001
(-99.50%)
133.05M
HMBLHUMBL Inc (PK)
US$ 0.0005
(0.00%)
111.65M
RDARRaadr Inc (PK)
US$ 0.0008
(0.00%)
94.31M

BAYZF Discussion

View Posts
Pastortec Pastortec 10 months ago
BAYER i recommend buy VOIS. The company that sell the stocks sell with them all its patents and one of them can influence with certain on your future sales.
πŸ‘οΈ0
mm41 mm41 12 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 12 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 12 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 12 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 12 months ago
The cheapest blue-chip stock . buy for a good long term
πŸ‘οΈ0
debunker1 debunker1 7 years ago
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
πŸ‘οΈ0
trendmkr trendmkr 9 years ago
A Look at the Science Behind Bayer’s Latest Buy

http://marketexclusive.com/a-look-at-the-science-behind-bayers-latest-buy/1194/
πŸ‘οΈ0
MasterofCoin15 MasterofCoin15 10 years ago
this stock don't play... up 50% since last year..
πŸ‘οΈ0
dragonball dragonball 15 years ago
how come this board is dead?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Yes, hope so eom
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
well it must be good if it made it to phase 3
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
maybe its a cancer drug? dont know oncological maybe. ?
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
very true. I will be picking up 100 shares and just letting it ride you think it might dip a bit?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
no,if Management has time to talk to me, they are not busy enough. I will let them be the PPS is good imo

πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
what exactly does nexevar do?
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
seriously though this looks like a pretty good company have you spoken to management?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
then you are about to move on up, to the east side to a deluxe apartment in the sky when you take this new brand of bayer pill lol
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
yes i do

πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Knowing your alias you take the dollar store brand lol

j/k
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
Is this bayer like the one in my medicine cabinet
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Bayer And Onyx Say 39% Progress On Phase III Nexavar Trial In Patients With Advanced Kidney Cancer - Quick Facts [BAY]

11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.

Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.

The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.

http://realtimetraders.com/sp/breakingnews.asp?vid=9625264



πŸ‘οΈ0